ANDA 78605, held by Teva Pharmaceuticals. Montelukast Sodium.
As of Nov 21, 2026, ANDA 78605 (Montelukast Sodium), held by Teva Pharmaceuticals, was first approved by FDA on Aug 3, 2012, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2012 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Montelukast SodiumEQ 10MG BASE · tablet;oral | Montelukast Sodium | Rx |
| Jul 23, 2020 | Supplement 13Labeling · Standard review | Approved | None posted |
| Apr 1, 2020 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 18, 2018 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 12, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Mar 16, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 16, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 25, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Feb 6, 2013 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 13, 2012 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 12, 2012 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 3, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters